$ASMB
Assembly Biosciences Inc

2020 Q3 Form 10-Q Financial Statement

#000156459020051470 Filed on November 05, 2020

View on sec.gov

Income Statement

Concept 2020 Q3 2019 Q4 2019 Q3
Revenue $34.61M $4.767M $4.231M
YoY Change 718.03% 27.63% -1.28%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $11.69M $10.83M $8.490M
YoY Change 37.69% 22.93% 9.55%
% of Gross Profit
Research & Development $26.94M $22.62M $21.74M
YoY Change 23.92% 6.45% 13.77%
% of Gross Profit
Depreciation & Amortization $100.0K $110.0K $100.0K
YoY Change 0.0% -35.29% -50.0%
% of Gross Profit
Operating Expenses $38.63M $33.45M $30.22M
YoY Change 27.81% 11.29% 12.52%
Operating Profit
YoY Change
Interest Expense $670.0K $860.0K $980.0K
YoY Change -31.63% -33.85% -4.85%
% of Operating Profit
Other Income/Expense, Net $0.00 $0.00
YoY Change -100.0%
Pretax Income -$3.350M -$27.83M -$25.01M
YoY Change -86.61% 11.23% 16.1%
Income Tax -$740.0K -$15.00K
% Of Pretax Income
Net Earnings -$3.349M -$27.08M -$25.00M
YoY Change -86.6% 3.53% 16.07%
Net Earnings / Revenue -9.68% -568.16% -590.76%
Basic Earnings Per Share -$0.09 -$0.96
Diluted Earnings Per Share -$0.09 -$976.2K -$0.96
COMMON SHARES
Basic Shares Outstanding 25.71M
Diluted Shares Outstanding 25.91M

Balance Sheet

Concept 2020 Q3 2019 Q4 2019 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $237.9M $274.0M $156.9M
YoY Change 51.59% 25.66% -32.9%
Cash & Equivalents $58.31M $46.73M $24.87M
Short-Term Investments $179.6M $227.3M $132.1M
Other Short-Term Assets $4.900M $5.400M $5.400M
YoY Change -9.26% 170.0% 63.64%
Inventory
Prepaid Expenses
Receivables $3.600M $3.374M $2.900M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $246.4M $282.8M $165.3M
YoY Change 49.06% 27.09% -31.09%
LONG-TERM ASSETS
Property, Plant & Equipment $1.904M $1.830M $1.931M
YoY Change -1.4% 228.55% 274.37%
Goodwill $12.64M
YoY Change 0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $6.000M $1.684M $1.700M
YoY Change 252.94% -49.7%
Total Long-Term Assets $59.90M $57.13M $58.00M
YoY Change 3.28% 25.44% 34.56%
TOTAL ASSETS
Total Short-Term Assets $246.4M $282.8M $165.3M
Total Long-Term Assets $59.90M $57.13M $58.00M
Total Assets $306.3M $339.9M $223.3M
YoY Change 37.17% 26.81% -21.09%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.600M $1.731M $2.700M
YoY Change -40.74% -53.13% -10.0%
Accrued Expenses $7.404M $8.286M $9.430M
YoY Change -21.48% -14.39% 44.7%
Deferred Revenue $6.411M $6.151M
YoY Change 25.71%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $16.80M $24.44M $21.50M
YoY Change -21.85% 32.31% 47.15%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $16.40M $39.70M $42.10M
YoY Change -61.05% 11.2% 14.4%
Total Long-Term Liabilities $16.40M $39.70M $42.10M
YoY Change -61.05% 2.0% 8.13%
TOTAL LIABILITIES
Total Short-Term Liabilities $16.80M $24.44M $21.50M
Total Long-Term Liabilities $16.40M $39.70M $42.10M
Total Liabilities $35.80M $66.69M $66.90M
YoY Change -46.49% 16.2% 24.94%
SHAREHOLDERS EQUITY
Retained Earnings -$439.4M
YoY Change 28.57%
Common Stock $712.8M
YoY Change 28.95%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $270.5M $273.2M $156.5M
YoY Change
Total Liabilities & Shareholders Equity $306.3M $339.9M $223.3M
YoY Change 37.17% 26.81% -21.09%

Cashflow Statement

Concept 2020 Q3 2019 Q4 2019 Q3
OPERATING ACTIVITIES
Net Income -$3.349M -$27.08M -$25.00M
YoY Change -86.6% 3.53% 16.07%
Depreciation, Depletion And Amortization $100.0K $110.0K $100.0K
YoY Change 0.0% -35.29% -50.0%
Cash From Operating Activities $10.64M -$20.53M -$18.60M
YoY Change -157.2% 22.71% 11.51%
INVESTING ACTIVITIES
Capital Expenditures $0.00 -$10.00K $0.00
YoY Change -95.24% -100.0%
Acquisitions
YoY Change
Other Investing Activities -$49.88M -$95.00M $7.820M
YoY Change -737.85% 53.35% -110.63%
Cash From Investing Activities -$49.88M -$95.02M $7.810M
YoY Change -738.67% 52.86% -110.61%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 840.0K 137.4M 1.380M
YoY Change -39.13% 22803.33% -99.11%
NET CHANGE
Cash From Operating Activities 10.64M -20.53M -18.60M
Cash From Investing Activities -49.88M -95.02M 7.810M
Cash From Financing Activities 840.0K 137.4M 1.380M
Net Change In Cash -38.40M 21.87M -9.410M
YoY Change 308.08% -127.93% -114.35%
FREE CASH FLOW
Cash From Operating Activities $10.64M -$20.53M -$18.60M
Capital Expenditures $0.00 -$10.00K $0.00
Free Cash Flow $10.64M -$20.52M -$18.60M
YoY Change -157.2% 24.21% 11.78%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
142000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-984000
us-gaap Net Income Loss
NetIncomeLoss
-70550000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
514000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3763000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-1677000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
470000
asmb Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-3382000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
149327000
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
28659000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
44704000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
377000
us-gaap Share Based Compensation
ShareBasedCompensation
18106000
asmb Accretion And Amortization Of Investments In Marketable Debt Securities
AccretionAndAmortizationOfInvestmentsInMarketableDebtSecurities
80000
asmb Noncash Rent Expense
NoncashRentExpense
3463000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-70408000
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.96
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.64
asmb Noncash Rent Expense
NoncashRentExpense
3344000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-33000
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
0
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.74
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
35506042
CY2019Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
25912568
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
35321393
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
25765414
us-gaap Net Income Loss
NetIncomeLoss
-22734000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
377000
us-gaap Share Based Compensation
ShareBasedCompensation
14049000
asmb Accretion And Amortization Of Investments In Marketable Debt Securities
AccretionAndAmortizationOfInvestmentsInMarketableDebtSecurities
1503000
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-102000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
0
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-18000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
216000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-507000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
4296000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-120000
asmb Increase Decrease In Accrued Clinical Expenses
IncreaseDecreaseInAccruedClinicalExpenses
-375000
asmb Increase Decrease In Accrued Clinical Expenses
IncreaseDecreaseInAccruedClinicalExpenses
670000
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-877000
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-1000000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-28061000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-2241000
asmb Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-3188000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-37688000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-63539000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1539000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
153022000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
165252000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
166911000
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
35595000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
47355000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1445000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1716000
asmb Proceeds From Issuance Of Common Stock Under Employee Stock Purchase Plan
ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan
467000
asmb Proceeds From Issuance Of Common Stock Under Employee Stock Purchase Plan
ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan
515000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2231000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-16604000
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
24867000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
15261000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
267115000
CY2020Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
843000
CY2020Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-262000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6202000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-3349000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
270549000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
174707000
CY2019Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1385000
CY2019Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-18000
CY2019Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5410000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-24995000
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
156489000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
273217000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1445000
us-gaap Stock Issued During Period Value Employee Stock Ownership Plan
StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
467000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
43000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
18111000
us-gaap Net Income Loss
NetIncomeLoss
-22734000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
270549000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
210653000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1716000
us-gaap Stock Issued During Period Value Employee Stock Ownership Plan
StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
515000
us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
-4000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
142000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
14017000
us-gaap Net Income Loss
NetIncomeLoss
-70550000
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
156489000
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
asmb Number Of Approved Products
NumberOfApprovedProducts
0
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that may affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Significant estimates inherent in the preparation of the accompanying unaudited condensed consolidated financial statements include revenue recognition, clinical trial accruals, recoverability and useful lives (indefinite or finite) of intangible assets, assessment of impairment of goodwill, provisions for income taxes, amounts receivable and recognized as revenue under the Company’s collaboration agreements, measurement of operating lease liabilities, and the fair value of stock options, stock appreciation rights, and restricted stock units (RSUs) granted to employees, directors and consultants.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s estimates could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that these external factors could have an effect on the Company’s estimates and could cause actual results to differ materially from those estimates and assumptions.</p>
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-3349000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-24995000
us-gaap Net Income Loss
NetIncomeLoss
-22734000
us-gaap Net Income Loss
NetIncomeLoss
-70550000
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
35506042
CY2019Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
25912568
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
35321393
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
25765414
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.09
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.96
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.64
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.74
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7537699
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6163602
CY2020Q3 asmb Cash Equivalents At Carrying Value And Available For Sale Debt Securities Amortized Cost
CashEquivalentsAtCarryingValueAndAvailableForSaleDebtSecuritiesAmortizedCost
235943000
CY2020Q3 asmb Cash Equivalents At Carrying Value And Available For Sale Debt Securities Gross Unrealized Gain
CashEquivalentsAtCarryingValueAndAvailableForSaleDebtSecuritiesGrossUnrealizedGain
133000
CY2020Q3 asmb Cash Equivalents At Carrying Value And Available For Sale Debt Securities Gross Unrealized Loss
CashEquivalentsAtCarryingValueAndAvailableForSaleDebtSecuritiesGrossUnrealizedLoss
2000
CY2020Q3 asmb Cash Equivalents At Carrying Value And Available For Sale Debt Securities Estimated Fair Value
CashEquivalentsAtCarryingValueAndAvailableForSaleDebtSecuritiesEstimatedFairValue
236074000
CY2019Q4 asmb Cash Equivalents At Carrying Value And Available For Sale Debt Securities Amortized Cost
CashEquivalentsAtCarryingValueAndAvailableForSaleDebtSecuritiesAmortizedCost
269817000
CY2019Q4 asmb Cash Equivalents At Carrying Value And Available For Sale Debt Securities Gross Unrealized Gain
CashEquivalentsAtCarryingValueAndAvailableForSaleDebtSecuritiesGrossUnrealizedGain
79000
CY2019Q4 asmb Cash Equivalents At Carrying Value And Available For Sale Debt Securities Gross Unrealized Loss
CashEquivalentsAtCarryingValueAndAvailableForSaleDebtSecuritiesGrossUnrealizedLoss
7000
CY2019Q4 asmb Cash Equivalents At Carrying Value And Available For Sale Debt Securities Estimated Fair Value
CashEquivalentsAtCarryingValueAndAvailableForSaleDebtSecuritiesEstimatedFairValue
269889000
CY2020Q3 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
0
CY2020Q3 asmb Fair Value Assets Between Levels Transfers Amount
FairValueAssetsBetweenLevelsTransfersAmount
0
CY2019Q4 asmb Fair Value Assets Between Levels Transfers Amount
FairValueAssetsBetweenLevelsTransfersAmount
0
CY2020Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3481000
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3030000
CY2020Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1577000
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1200000
CY2020Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1904000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1830000
CY2020Q3 us-gaap Depreciation
Depreciation
100000
CY2019Q3 us-gaap Depreciation
Depreciation
100000
us-gaap Depreciation
Depreciation
400000
us-gaap Depreciation
Depreciation
400000
CY2020Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
6172000
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5312000
CY2020Q3 asmb Accrued Restructuring Charges Current
AccruedRestructuringChargesCurrent
697000
CY2019Q4 asmb Accrued Restructuring Charges Current
AccruedRestructuringChargesCurrent
2094000
CY2020Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
535000
CY2019Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
880000
CY2020Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7404000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8286000
CY2019Q4 asmb Accrued Restructuring Charges Current
AccruedRestructuringChargesCurrent
2100000
CY2020Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2020Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2017Q4 asmb Initial Public Offering Value Of Shares Authorized
InitialPublicOfferingValueOfSharesAuthorized
250000000.0
asmb Warrants Exercisable Description
WarrantsExercisableDescription
under their terms, the outstanding pre-funded warrants to purchase shares of the Company’s common stock generally may not be exercised if the holder’s ownership of the Company’s common stock would exceed 19.99% following such exercise.
CY2020Q3 asmb Number Of Warrants Exercised
NumberOfWarrantsExercised
0
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
1900000
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
3000000
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
4600000
CY2019Q4 asmb Proceeds From Sale Of Pre Funded Warrants
ProceedsFromSaleOfPreFundedWarrants
37500000
CY2020Q3 asmb Initial Public Offering Value Of Shares Authorized
InitialPublicOfferingValueOfSharesAuthorized
300000000.0
CY2020Q3 asmb Initial Public Offering Value Of Shares Authorized
InitialPublicOfferingValueOfSharesAuthorized
300000000.0
CY2020Q3 asmb Common Stock Remaining Shares Available For Sale
CommonStockRemainingSharesAvailableForSale
21400000
CY2020Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
2424242
CY2019Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
2439538
CY2019Q3 asmb Number Of Warrants Exercised
NumberOfWarrantsExercised
0
asmb Number Of Warrants Exercised
NumberOfWarrantsExercised
0
asmb Number Of Warrants Exercised
NumberOfWarrantsExercised
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
11.01
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
10.79
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
2000000.0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
1600000
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6048000
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2019Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5404000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
18106000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
14049000
CY2020Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
8987000
us-gaap Operating Lease Cost
OperatingLeaseCost
3344000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
520000
us-gaap Variable Lease Cost
VariableLeaseCost
900000
CY2020Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
27800000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y9M18D
CY2019Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
37048000
asmb Contract With Customer Liability In Additions
ContractWithCustomerLiabilityInAdditions
40000000
asmb Contract With Customer Liability In Deduction
ContractWithCustomerLiabilityInDeduction
68061000
CY2018Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
40660000
asmb Contract With Customer Liability In Additions
ContractWithCustomerLiabilityInAdditions
0
asmb Contract With Customer Liability In Deduction
ContractWithCustomerLiabilityInDeduction
2241000
CY2019Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
38419000
CY2020Q3 us-gaap Purchase Commitment Remaining Minimum Amount Committed
PurchaseCommitmentRemainingMinimumAmountCommitted
800000
CY2020Q3 asmb Performance Milestone Payment
PerformanceMilestonePayment
100000
asmb Performance Milestone Payment
PerformanceMilestonePayment
100000
CY2020Q3 asmb Sublicensing Fee
SublicensingFee
700000
asmb Sublicensing Fee
SublicensingFee
700000
CY2020Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
10800000
CY2020Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
10400000
CY2020Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
1164000
CY2019Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
1136000
us-gaap Operating Lease Cost
OperatingLeaseCost
3463000
CY2020Q3 us-gaap Short Term Lease Cost
ShortTermLeaseCost
101000
CY2019Q3 us-gaap Short Term Lease Cost
ShortTermLeaseCost
88000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
301000
CY2020Q3 us-gaap Variable Lease Cost
VariableLeaseCost
409000
CY2019Q3 us-gaap Variable Lease Cost
VariableLeaseCost
301000
us-gaap Variable Lease Cost
VariableLeaseCost
1101000
CY2020Q3 us-gaap Lease Cost
LeaseCost
1674000
CY2019Q3 us-gaap Lease Cost
LeaseCost
1525000
us-gaap Lease Cost
LeaseCost
4865000
us-gaap Lease Cost
LeaseCost
4764000
us-gaap Operating Lease Payments
OperatingLeasePayments
3382000
us-gaap Operating Lease Payments
OperatingLeasePayments
3188000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1063000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
15261000
CY2020Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y
CY2019Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y8M12D
CY2020Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.093
CY2019Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.094
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
1208000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
4182000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
3818000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
3436000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
12644000
CY2020Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
1871000
CY2020Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
10773000

Files In Submission

Name View Source Status
0001564590-20-051470-index-headers.html Edgar Link pending
0001564590-20-051470-index.html Edgar Link pending
0001564590-20-051470.txt Edgar Link pending
0001564590-20-051470-xbrl.zip Edgar Link pending
asmb-10q_20200930.htm Edgar Link pending
asmb-10q_20200930_htm.xml Edgar Link completed
asmb-20200930.xsd Edgar Link pending
asmb-20200930_cal.xml Edgar Link unprocessable
asmb-20200930_def.xml Edgar Link unprocessable
asmb-20200930_lab.xml Edgar Link unprocessable
asmb-20200930_pre.xml Edgar Link unprocessable
asmb-ex101_29.htm Edgar Link pending
asmb-ex102_30.htm Edgar Link pending
asmb-ex103_251.htm Edgar Link pending
asmb-ex311_7.htm Edgar Link pending
asmb-ex312_9.htm Edgar Link pending
asmb-ex321_6.htm Edgar Link pending
asmb-ex322_8.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
gk3dgyjrqhkc000001.jpg Edgar Link pending
glsa0uz20nmn000001.jpg Edgar Link pending
glsa0uz20nmn000002.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending